Northwire Canada EditionTuesday, November 3, 2026
Sign inSubscribe
Northwire
⌕
Gold 3,938.10 −0.8% Silver 49.67 −2.4% Copper 6.39 −2.7% Oil 95.81 −0.7% Palladium 933.00 −3.7% CTN 0.045 + EQTY 0.090 +5.9% MON 0.395 +0.0% GAL 0.350 +1.4% MUR 0.160 +0.0% BARU 0.040 +0.0% GGO 1.02 +1.0% DNG 5.30 +0.8% VCU 0.770 +0.0% NVX 0.950 +4.4% LOD 0.200 −9.1% OBUL 0.400 +5.3% VMXX 0.390 +6.8% TGOL 0.130 +0.0% WINS 0.075 +0.0% EAU 0.045 +0.0% Gold 3,938.10 −0.8% Silver 49.67 −2.4% Copper 6.39 −2.7% Oil 95.81 −0.7% Palladium 933.00 −3.7% CTN 0.045 + EQTY 0.090 +5.9% MON 0.395 +0.0% GAL 0.350 +1.4% MUR 0.160 +0.0% BARU 0.040 +0.0% GGO 1.02 +1.0% DNG 5.30 +0.8% VCU 0.770 +0.0% NVX 0.950 +4.4% LOD 0.200 −9.1% OBUL 0.400 +5.3% VMXX 0.390 +6.8% TGOL 0.130 +0.0% WINS 0.075 +0.0% EAU 0.045 +0.0%
Other Routine +

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution

MindBio Pivots from Failed Psychedelic Trial to AI Voice Detection Amidst Dilution Concerns

By The Northwire Desk — AI Analysis May 14, 2026 · 08:30 MBIO · 1.04 MindBio Therapeutics Corp.
Executive Summary
  • The most recent news releases (May 13 and May 14, 2026) feature media coverage highlighting MindBio's proprietary AI voice analysis technology for detecting drug and alcohol impairment.
  • The company is developing Edge-AI kiosks targeting high-stakes industries like mining, aviation, construction, and law enforcement.
  • Technology claims include the use of over 50 million data points to predict intoxication through speech patterns (pitch, rhythm, articulation).
  • A fatigue prediction model has been developed as an add-on feature for the Edge AI kiosks, with commercial testing on track for late Q2 2026.
  • This news aligns with previous announcements regarding patent filings in April 2026 and the deployment of engineers to South America in February 2026.
Material Impact
  • The news is consistent with the company's stated roadmap from earlier in 2026 (patent filings, hardware development timeline).
  • It does not introduce new revenue streams or confirmed contracts that would materially alter the financial outlook immediately.
  • The clinical trial failure for MB22001 (LSD microdose) in November 2025 remains a significant historical negative event that necessitates this pivot to AI, increasing execution risk on the new business model.
  • Financing history shows repeated capital raises ($650k to $1.5M targets in early 2026), indicating ongoing cash burn and dilution pressure which offsets positive sentiment from product updates.
  • The media feature nature of the May releases suggests marketing efforts rather than hard commercial milestones, limiting immediate material impact on stock price beyond sentiment.
MBIO · Price
Company Overview
  • Company: MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF).
  • Flagship Project 1 (Legacy): MB22001 (Microdosed LSD for Major Depressive Disorder). Phase 2B trial results in Nov 2025 showed no statistical superiority over placebo, leading to a strategic pivot.
  • Flagship Project 2 (Current Focus): AI-driven voice analysis platform for intoxication and fatigue detection. Includes "Booze AI" consumer app and Edge-AI kiosks for enterprise use.
  • Development Stage: Hardware prototype nearing completion; commercial testing scheduled for late Q2 2026. Software models trained on >50 million data points.
  • Target Markets: Mining, aviation, construction, law enforcement (Workplace safety/substance testing sector estimated at $47 billion).
Read the original news release →

More from MindBio Therapeutics Corp.

Jun 09, 2026 · 07:00

From failed psychedelics to unproven AI kiosks: MindBio bets its survival on voice analytics, but cash burn and dilution loom.

Production / Operations Jun 04, 2026 · 11:12

MindBio’s Voice AI Pivot Buys Time, But Cash Runway and Dilution Risk Keep the Stock in the Red Zone

Other May 15, 2026 · 08:30

MindBio's AI Pivot Masks Failed Drug Trial and Dilution Risk

Other May 13, 2026 · 08:30

MindBio Pivots to AI Voice Tech After Clinical Setback; Dilution Risks Loom

Other May 11, 2026 · 08:45

MindBio Pivots from Clinical Failure to AI Voice Analytics, But Dilution Risks Loom

Other May 11, 2026 · 08:30

MindBio Pivots from Failed Psychedelic Trial to AI Safety Tech Amidst Cash Burn Concerns

Other